CSL Limited (CMXHF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

CSL Limited (CMXHF) Healthcare & Pipeline Overview

CSL Limited is a global biotechnology company specializing in plasma-derived therapies and influenza vaccines, operating through its CSL Behring and Seqirus segments. With a strong presence in immunology, hematology, and influenza prevention, CSL serves patients in over 100 countries, driven by research and development and strategic global partnerships.

What Is the Investment Thesis for CMXHF?

CSL Limited presents a notable research candidate due to its leading position in the growing plasma-derived therapies and influenza vaccine markets. The company's consistent revenue growth, driven by increasing demand for its core products, is a key value driver. CSL's robust R&D pipeline and strategic acquisitions are expected to fuel future growth. With a P/E ratio of 24.08 and a dividend yield of 3.02%, CSL offers a blend of growth and income potential. Ongoing catalysts include expansion into new therapeutic areas and geographic markets. Potential risks include regulatory changes and competition from biosimilars. The company's strong financial performance, with a profit margin of 9.2% and a gross margin of 48.6%, supports its long-term growth prospects.

Based on FMP financials and quantitative analysis

CMXHF Key Highlights

Market capitalization of $60.4B, reflecting its significant presence in the biotechnology industry.

• P/E ratio of 24.08, indicating investor confidence in its earnings potential.
• Profit margin of 9.2%, demonstrating efficient operations and profitability.
• Gross margin of 48.6%, showcasing its ability to generate revenue from its products.
• Dividend yield of 3.02%, providing a steady income stream for investors.

Who Are CMXHF's Competitors?

CMXHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are CMXHF's Key Strengths?

Leading position in plasma-derived therapies and influenza vaccines.

• Strong global manufacturing and distribution network.
• Robust research and development pipeline.
• Experienced management team.

What Are CMXHF's Weaknesses?

Dependence on plasma supply.

• Exposure to regulatory risks.
• Competition from biosimilars.
• Fluctuations in influenza vaccine demand.

What Could Drive CMXHF Stock Higher?

Expansion into new therapeutic areas, such as neurology and oncology, driving revenue growth.

• Geographic expansion in emerging markets, particularly China and India, increasing market share.
• Development and launch of novel therapies, such as gene therapies and cell therapies, addressing unmet medical needs.
• Strategic acquisitions to further strengthen its position in the biotechnology industry.
• Increasing demand for influenza vaccines, driven by increasing awareness of the importance of vaccination.

What Are the Key Risks for CMXHF?

Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.

• Changes in regulatory requirements impacting product approvals and market access.
• Competition from other biotechnology companies, including biosimilars, eroding market share.
• Economic downturns reducing healthcare spending and demand for products.
• Supply chain disruptions affecting the availability of plasma and other raw materials.
• Dependence on plasma supply, which can be affected by various factors, including disease outbreaks and economic conditions.

What Are the Growth Opportunities for CMXHF?

• Expansion into new therapeutic areas: CSL has the opportunity to leverage its expertise in plasma fractionation and biomanufacturing to expand into new therapeutic areas, such as neurology and oncology. This expansion could drive significant revenue growth and diversification. The market for neurological disorders is projected to reach $15 billion by 2030, presenting a substantial opportunity for CSL.
• Geographic expansion: CSL can further expand its geographic presence, particularly in emerging markets such as China and India. These markets offer significant growth potential due to their large populations and increasing healthcare spending. The Chinese biopharmaceutical market is expected to grow at a rate of 15% per year over the next five years.
• Development of novel therapies: CSL's robust R&D pipeline includes several novel therapies in development, such as gene therapies and cell therapies. These therapies have the potential to address unmet medical needs and generate significant revenue. CSL is investing heavily in these areas, with R&D spending expected to increase by 10% annually.
• Strategic acquisitions: CSL has a history of successful acquisitions, which have enabled it to expand its product portfolio and geographic reach. The company can continue to pursue strategic acquisitions to further strengthen its position in the biotechnology industry. CSL has allocated $2 billion for potential acquisitions over the next three years.
• Increased demand for influenza vaccines: The global demand for influenza vaccines is expected to increase, driven by increasing awareness of the importance of vaccination and the development of more effective vaccines. CSL, through its Seqirus segment, is well-positioned to capitalize on this trend. The influenza vaccine market is projected to reach $10 billion by 2028.

What Are CMXHF's Competitive Advantages?

• Expertise in plasma fractionation and biomanufacturing.
• Strong global manufacturing network.
• Robust research and development pipeline.
• Established relationships with healthcare providers and regulatory agencies.
• High barriers to entry in the plasma-derived therapies market.

What Does CMXHF Do?

Founded in 1916 in Australia, CSL Limited has evolved into a global biotechnology leader. Originally established as the Commonwealth Serum Laboratories to serve Australia's health needs, CSL has expanded its operations internationally through strategic acquisitions and organic growth. The company operates through two primary segments: CSL Behring and Seqirus. CSL Behring focuses on plasma-derived therapies, offering a range of products for treating immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. These therapies are derived from human plasma and manufactured using advanced fractionation and purification techniques. Seqirus, on the other hand, specializes in influenza vaccines, developing and manufacturing both seasonal and pandemic influenza vaccines. Seqirus is one of the largest influenza vaccine companies in the world, playing a critical role in global influenza prevention efforts. CSL Limited has a significant global presence, with operations in Australia, the United States, Germany, the United Kingdom, Switzerland, and China, among other countries. The company's commitment to research and development drives innovation in its core therapeutic areas, ensuring a pipeline of new and improved therapies for patients worldwide. CSL's competitive positioning is strengthened by its expertise in plasma fractionation, its global manufacturing network, and its strong relationships with healthcare providers and regulatory agencies.

What Products and Services Does CMXHF Offer?

• Researches and develops biopharmaceutical products.
• Manufactures plasma-derived therapies for immunodeficiency and bleeding disorders.
• Produces recombinant therapies for various medical conditions.
• Develops and distributes influenza vaccines.
• Offers therapies for hereditary angioedema and Alpha-1 antitrypsin deficiency.
• Provides treatments for neurological disorders.
• Conducts research on plasma and non-plasma therapies.
• Commercializes intellectual property through licensing and royalties.

How Does CMXHF Make Money?

• Develops and manufactures biopharmaceutical products.
• Sells plasma-derived therapies and influenza vaccines to healthcare providers and patients.
• Generates revenue through product sales and licensing agreements.
• Invests in research and development to create new and improved therapies.

What Industry Does CMXHF Operate In?

CSL Limited operates in the biotechnology industry, which is characterized by rapid innovation and increasing demand for advanced therapies. The global market for plasma-derived therapies is expected to grow significantly, driven by the rising prevalence of chronic diseases and the increasing adoption of these therapies in emerging markets. The influenza vaccine market is also experiencing growth, driven by increasing awareness of the importance of vaccination and the development of more effective vaccines. CSL competes with other major players in the biotechnology industry, including ARGNF (Grifols), DSNKY (Daiichi Sankyo), HOCPY (Hoffmann-La Roche), IPSEY (Ipsen), and MKGAF (Merck KGaA).

Who Are CMXHF's Key Customers?

• Patients with immunodeficiency disorders.
• Patients with bleeding disorders.
• Individuals seeking protection against influenza.
• Healthcare providers and hospitals.
• Government agencies and public health organizations.

Company Profile

CSL Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Melbourne, AU. The company is led by CEO Gordon Naylor DipCompSc. CMXHF has traded publicly since 2005.

Return on equity for CSL Limited stands at 7.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.8%, showing how much profit it generates from its asset base. CMXHF trades at a trailing price-to-earnings ratio of 24.08, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 9.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.57 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.2%, the inverse of the P/E and a quick read on earnings relative to price.

CMXHF Valuation & Market Position

With a $60.4B market cap, CSL Limited sits in the large-cap segment of the market. Relative to its peer group, CMXHF's quantitative score of 48/100 is below the peer average of 65/100.

Quarterly Financial Performance: CSL Limited

Revenue for CSL Limited came in at $7.30B during Q4 FY2026, a 13.5% contraction versus the preceding quarter. The company recorded a net loss of $2.93B, with diluted EPS of $-6.13. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, CMXHF averaged $0.24 in diluted EPS.

CSL Limited's Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 4.63 places it in the safe zone, indicating low near-term bankruptcy risk.

CSL Limited has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 1.2% below estimates on average.

CMXHF Financials

CMXHF Latest News

CMXHF Analyst Consensus

CMXHF MoonshotScore

CMXHF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources